Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897259 | 1.00 | LMNA (0.32) | LMNASLC22A2SLC22A1GRIN2DGRIN3B | |
| SCHEMBL1897838 | 1.00 | LMNA (0.32) | LMNASLC22A2SLC22A1GRIN2DGRIN3B | |
| SCHEMBL12765779 | 0.95 | LMNA (0.32) | LMNASLC22A2SLC22A1GRIN2DGRIN3B | |
| SCHEMBL12765509 | 0.85 | — | — | |
| SCHEMBL12765764 | 0.81 | LMNA (0.35) | LMNASLC22A2SLC22A1GRIN2DGRIN3B | |
| SCHEMBL28233988 | 0.75 | CYP2C9 (0.43) | — | |
| SCHEMBL12765492 | 0.75 | — | — | |
| SCHEMBL12765771 | 0.75 | CYP2C9 (0.38) | — | |
| SCHEMBL192524 | 0.74 | GRIN2D (0.44) | LMNASLC22A2SLC22A1GRIN2DGRIN3B | |
| SCHEMBL13558671 | 0.72 | GRIN1 (0.60) | LMNASLC22A2SLC22A1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092039-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV BARCELONA (ES) | 2026-04-02 | — | — | US | disclosed |
| EP-4676916-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Universitat De Barcelona (ES) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024184305-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITAT DE BARCELONA (ES) | 2024-09-12 | — | — | WO | disclosed |
| WO-2023110138-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| EP-4192813-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-4192812-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-4192814-A1 | INHIBITORS OF TRANSGLUTAMINASES | Zedira GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| WO-2023275336-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275337-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275333-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| US-20110065762-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
| US-7880001-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | KOWA COMPANY, LTD., (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-30 | — | — | US | disclosed |
| EP-1751108-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005108368-A1 | ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050245745-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050245534-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222316-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | LMNA 4105/4885SLC22A2 2369/4885SLC22A1 1966/4885 |
| US-20100075943-A1 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME | HSD11B1, HSD3B1, CYP46A1 | LMNA 2573/4885SLC22A2 2122/4885SLC22A1 1351/4885 |
| US-20110065762-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | MAVS, SLC30A5, HAVCR2 | LMNA 1701/4885SLC22A2 252/4885SLC22A1 222/4885 |
| US-20090192141-A1 | METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD17B1, HSD11B2 | LMNA 3437/4885SLC22A2 2609/4885SLC22A1 2454/4885 |
| US-20050245745-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | LMNA 4105/4885SLC22A2 2369/4885SLC22A1 1966/4885 |
| US-20050277647-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | LMNA 4105/4885SLC22A2 2369/4885SLC22A1 1966/4885 |
| US-20050245534-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | LMNA 4105/4885SLC22A2 2369/4885SLC22A1 1966/4885 |
| US-20260092039-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE2, BACE1, GLS2 | LMNA 699/4885SLC22A2 828/4885SLC22A1 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.